U.S. Stock News

If you are wondering whether Easterly Government Properties is fairly priced or offering value right now, this article will walk you through what the numbers actually say. The stock last closed at US$23.79, with a 30 day return of 6.3% and an 11.6% return year to date, set against a 3.1% decline over the past year and a 23.7% and 37.1% decline over the past 3 and 5 years respectively. Recent coverage of Easterly Government Properties has focused on its position as a real estate investment...

What is moving Amphastar Pharmaceuticals now? Amphastar Pharmaceuticals (AMPH) has drawn investor attention after its recent share performance, with the stock around $27.55 and short term returns mixed between the past week, month and past 3 months. See our latest analysis for Amphastar Pharmaceuticals. At around $27.55, Amphastar Pharmaceuticals has given investors a mixed ride, with recent share price returns over the past week and month soft, while the 90 day share price return of 5.72%...

If you are wondering whether ACM Research's share price still lines up with its fundamentals, this article walks through what the current valuation metrics are actually telling you. The stock last closed at US$64.10, with returns of 17.9% over 7 days, 24.9% over 30 days, 42.8% year to date, 176.3% over 1 year and 391.2% over 3 years, which naturally raises questions about how the recent price compares with estimated fair value. Recent news around ACM Research has focused on its role in...

If you are wondering whether Tencent Music Entertainment Group's current share price reflects its true worth, you are not alone. This article is built to help you make sense of the numbers. The stock closed at US$15.15, with returns of a 4.9% decline over the last 7 days, a 13.8% decline over 30 days, a 15.2% decline year to date, a 20.2% gain over 1 year, an 87.1% gain over 3 years, and a 42.3% decline over 5 years. Recent moves therefore sit within a mixed longer term picture. Recent...

If you are wondering whether Kodiak AI at around US$8.35 is starting to look interesting on price alone, it helps to step back and look at what the current market is implying about its value. Over the short term, the stock has been under pressure, with a 7 day return of 4.4% decline, a 30 day return of 11.1% decline, and a year to date return of 22.9% decline, contributing to a 24.4% decline over the past year. This weaker share price backdrop is unfolding alongside broader evergreen...

In early February 2026, PotlatchDeltic Corporation was removed from the NASDAQ Composite Index, while multiple long-running ESOP-related shelf registrations for common stock were formally closed. This combination highlights how a technical index change, rather than routine employee stock plan administration, can have an outsized influence on trading flows and investor attention. Next, we’ll examine how PotlatchDeltic’s removal from the NASDAQ Composite Index could affect its existing...

Simon Property Group (SPG) has drawn fresh attention after unveiling a transformational plan for the former Neiman Marcus space at Boston's Copley Place, introducing new luxury retailers and high profile dining concepts. See our latest analysis for Simon Property Group. Recent news has arrived alongside mixed share price moves, with Simon Property Group's 1 day share price return of a 1.71% decline and 7 day share price return of a 2.96% decline contrasting with a 30 day share price return of...

FirstEnergy (NYSE:FE) announced a 4.5% increase to its quarterly dividend. The company also provided forward dividend guidance, outlining expectations for higher annual payouts. Management linked the dividend update to confidence in the company’s ongoing transformation and operations. For income focused investors watching utilities, this dividend move from FirstEnergy comes on top of a solid share price run. NYSE:FE is trading at $48.84, with the stock up 3.9% over the past week and 7.8%...

If you are wondering whether Tower Semiconductor is still priced reasonably after its strong run, or if you might be looking at a stretched stock, this article walks through what the current share price could mean for you. The stock last closed at US$133.58, with returns of 3.5% over 7 days, 7.1% over 30 days, 9.7% year to date, 177.1% over 1 year and 321.5% over 5 years. This naturally raises questions about what is already baked into the price. Recent news flow around Tower Semiconductor...

Earnings, guidance and buybacks set the tone for Cirrus Logic (CRUS) Cirrus Logic (CRUS) has just combined a fresh earnings release, new quarterly revenue guidance and an update on its ongoing share repurchases, giving investors several new data points to assess the stock. See our latest analysis for Cirrus Logic. The recent earnings, fresh quarterly revenue guidance and active buyback program come against a backdrop of firm positive momentum, with a 30 day share price return of 14.96% and a...

If you are wondering whether Johnson Controls International is priced attractively right now, you are not alone. This article will walk through what the current share price could mean for investors focused on value. The stock last closed at US$138.57, with returns of 4.6% over 7 days, 23.6% over 30 days, 13.3% year to date, 58.9% over 1 year, 128.6% over 3 years and 175.8% over 5 years. This raises fair questions about how much of the story is already reflected in the price. Recent attention...

Cummins (CMI) is back in focus after its latest quarterly earnings update, a mixed market reaction to GAAP results, fresh 2026 guidance, a higher dividend, and sharper priorities for its Accelera business. See our latest analysis for Cummins. The recent earnings volatility, updated 2026 guidance and higher dividend have all landed against a strong run in the shares. Cummins’ 90 day share price return of 27.28% and 1 year total shareholder return of 62.62% point to momentum that has been...

IDEX Corporation recently reported fourth-quarter 2025 results showing higher sales of US$899.1 million and net income of US$128.3 million, while also continuing its long-running share repurchase program. Soon after these results, IDEX moved to eliminate the role of Senior Vice President, Chief Strategy and Innovation Officer Roopa Unnikrishnan, signaling an organizational shift in how it approaches growth and innovation. We’ll now consider how the stronger quarter, especially momentum in...

G-III Apparel Group recently advanced the revival of DKNY and Donna Karan New York by extending Hailey Bieber’s global ambassador role for DKNY and launching Spring 2026 campaigns featuring Adriana Lima, Joan Smalls, and Grace Elizabeth across key retail and digital channels. By pairing high-impact celebrity campaigns with curated edits that emphasize each model’s personal expression, the company is sharpening the distinct identities of its owned brands and potentially strengthening consumer...

If you are wondering whether Futu Holdings at around US$147.48 is still good value or starting to look stretched, you are not alone. The stock has seen a 1.7% decline over the last 7 days and a 19.9% decline over the last 30 days, even though the 1 year return sits at 25.1% and the 3 year return is a very large 201.3%. Recent news coverage has focused on Futu Holdings as a key online broker for Chinese equities and global markets, with attention on how investor trading activity and...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Travel + Leisure fair value estimate is US$100 Current share...

IAC (NasdaqGS:IAC) reported that digital revenue showed resilience despite industry-wide disruption from falling print and web traffic and the impact of AI on digital publishing. Management highlighted new digital products and repositioning efforts that are intended to align the portfolio with changing media consumption trends. The company acknowledged overall revenue declines and profitability shortfalls, while pointing to ongoing share buybacks as part of its capital allocation...

BioCryst Pharmaceuticals recently acquired Astria Therapeutics for about US$700.00 million and announced that it has presented nine hereditary angioedema abstracts, including new data on ORLADEYO and long-acting antibody navenibart, at the 2026 AAAAI Annual Meeting. Beyond expanding its hereditary angioedema portfolio, the company’s positive interim ALPHA-SOLAR trial results for navenibart highlight a potential shift toward less frequent, long-acting preventive treatment options. We’ll now...

Some Ameriprise Financial, Inc. ( NYSE:AMP ) shareholders may be a little concerned to see that the Chairman & CEO...

Estée Lauder Companies (NYSE:EL) has filed a federal lawsuit against Walmart, alleging the retailer sold counterfeit skincare and fragrance products online. The suit targets products tied to brands including Aveda, Clinique, La Mer, Le Labo, and Tom Ford. Estée Lauder is seeking an injunction and monetary damages in response to the alleged counterfeit sales. For investors watching NYSE:EL, this legal move comes with the stock at a share price of $106.42. The company’s recent performance has...

Why the latest PAPZIMEOS endorsement matters for Precigen Precigen (PGEN) is back in focus after a new consensus paper from 16 physicians recommended its drug PAPZIMEOS as the standard of care for adults with recurrent respiratory papillomatosis, building on recent US and European regulatory milestones. See our latest analysis for Precigen. Precigen’s share price has moved to $4.74, with an 11.79% 7 day share price return and 13.67% 30 day share price return, while the 1 year total...

First American Financial (FAF) just wrapped up FY 2025 with Q4 revenue of US$2.0 billion and basic EPS of US$2.06, supported by trailing 12 month revenue of US$7.5 billion and EPS of US$6.02. Over recent quarters, the company has seen revenue move from US$1.6 billion and EPS of US$0.71 in Q1 2025 to US$2.0 billion and EPS of US$2.06 in Q4 2025, while trailing net profit margin sits at 8.3% compared with 2.1% a year earlier. This points to a period where profitability has become a much bigger...

Sylvamo (SLVM) just posted its FY 2025 third quarter numbers, reporting revenue of US$846 million and basic EPS of US$1.43 alongside net income of US$57 million. The company’s quarterly revenue moved from US$970 million in Q4 2024 to US$821 million in Q1 2025, US$794 million in Q2, and then US$846 million in Q3. Over the same period, basic EPS went from US$1.98 to US$0.67, US$0.37, and then US$1.43. These shifts give investors more detail for evaluating how recent performance trends relate to...

If you are looking at NovoCure and wondering whether the current share price really reflects its potential, this article will walk through what the numbers are saying about value. The stock last closed at US$12.53, with a recent 7 day return of 23.6%, a 30 day return of a 9.0% decline, a year to date return of a 4.5% decline, and a 1 year return of a 44.3% decline, which gives a mixed picture of sentiment over different time frames. Recent news around NovoCure has focused on the ongoing...